Imura H, Endo J, Ohkura H, Ishii M, Ariyoshi Y, Abe O, Masamune O, Nishimoto Y, Fukushi Y, Orikasa S
Gan To Kagaku Ryoho. 1987 May;14(5 Pt 1):1322-31.
The clinical significance of serum sialyl SSEA-1 antigen was evaluated using the sera of 1261 patients with malignant tumors and 717 patients with non-malignant diseases measured with Otsuka Assay Laboratories' RIA Kits. The results indicate that the antigen was frequently elevated in the sera from the patients with various adenocarcinomas, including lung (45%), pancreas (64%) and ovary (57%). The false positive incidence of antigens in the sera from the patients with non-malignant disorders was as low as 4.9%. No correlation was observed with other tumor markers examined in this study, and the diagnostic efficiency increased significantly by the combined determination of sialyl SSEA-1 antigen level with other markers. The serial determination of the serum sialyl SSEA-1 antigen level has a clinical utility also in monitoring the patients with adenocarcinoma receiving surgical operation and/or chemotherapy as indicated by the results of the longitudinal observation of the patients.
使用大冢分析实验室的放射免疫分析试剂盒对1261例恶性肿瘤患者和717例非恶性疾病患者的血清进行检测，评估血清唾液酸化阶段特异性胚胎抗原-1（sialyl SSEA-1）抗原的临床意义。结果表明，该抗原在包括肺癌（45%）、胰腺癌（64%）和卵巢癌（57%）在内的各种腺癌患者的血清中经常升高。非恶性疾病患者血清中抗原的假阳性发生率低至4.9%。本研究中未观察到与其他检测的肿瘤标志物有相关性，并且通过联合检测唾液酸化SSEA-1抗原水平和其他标志物，诊断效率显著提高。患者的纵向观察结果表明，连续测定血清唾液酸化SSEA-1抗原水平在监测接受手术和/或化疗的腺癌患者方面也具有临床实用性。
